Some visit links earn us a commission.
Quick verdict
Henry Meds is the better pick for most patients on overall scoring. Henry built the cash-pay compounded GLP-1 category and still runs the cleanest version of it. Predictable bundled pricing and true month-to-month terms, though the semaglutide tiers moved behind signup in June 2026. Pivoted hard after the FDA shortage delisting and now leans on personalization-claim 503A pharmacies.
That said, Medvi wins on specific dimensions. Medvi runs a compounded-semaglutide and tirzepatide model at flat monthly pricing, with no lock-in and rapid intake. Comparable to Henry Meds and Mochi on price; less established clinical depth than Form Health or Knownwell. Best fit for cash-pay patients who want predictable monthly cost with minimal friction.
Side-by-side
| Henry Meds | Medvi | |
|---|---|---|
| Starts from | $297/mo (incl. medication) | $299/mo (incl. medication) |
| Monthly cost gap | Same monthly cash-pay total | |
| Lock-in | Month-to-month | Month-to-month |
| Time to prescription | 2 days | 2 days |
| Consultation type | Asynchronous | Asynchronous |
| Affiliate network | Impact | Direct |
Score by dimension
Scores out of 10, equal-weighted across five dimensions. How we score. The winner of each dimension is highlighted.
| Henry Meds | Medvi | |
|---|---|---|
| Pricing transparency | 8/10 | 8/10 |
| Cancellation terms | 9/10 | 8/10 |
| Onboarding experience | 8/10 | 7/10 |
| Medication options | 6/10 | 7/10 |
| Member reviews | 9/10 | 9/10 |
When to choose Henry Meds
Best for cheapest compounded
Buyers who want predictable flat-rate compounded semaglutide with no commitments and minimal friction.
Henry Meds wins on cancellation terms, onboarding experience on the dimensional scoring. The caveat: Patients who want branded Wegovy or Zepbound through insurance, or who want a high-touch coaching program. Note also: Subject of ongoing scrutiny over personalization-claim compounding post-shortage delisting (FDA Feb 2025).
When to choose Medvi
Best for flat compounded with no lock-in
Cash-pay patients who want flat predictable compounded GLP-1 pricing with no lock-in and same-week onboarding. Strong fit if you've taken GLP-1 before and want a simple ongoing prescription channel.
Medvi wins on medication options on the dimensional scoring. The caveat: Insurance-pathway shoppers, patients with multiple comorbidities needing clinical depth or anyone wanting branded Wegovy or Zepbound through standard PA. Note also: Compounded GLP-1 carries 503A regulatory exposure; see compounded callout
If cost is your main filter
Henry Meds and Medvi sit at the same entry-tier cash-pay total. Decide on lock-in and medication options, not price. Insurance changes the picture: if either program runs prior auth and your plan covers Wegovy or Zepbound, branded with copay can beat both cash-pay totals.
If lock-in is your main filter
Henry Meds (month-to-month) and Medvi (month-to-month) sit at the same cancellation tier. Read both cancellation policies directly before signing; the on-page summary covers the headline but not the deletion-of-account or refund-window edge cases.
FAQ
Is Henry Meds cheaper than Medvi?
Can I switch from Henry Meds to Medvi mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart → · Cost guide · Programs guide
